http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+05/26611041.html si-local-file:///var/storage/secattach/20260605/26611041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+05/26611041.html Fri, 05 Jun 2026 16:06:00 -0400 FEMY O.50783454 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+05/26611041.html si-local-file:///var/storage/secattach/20260605/26611041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+05/26611041.html Fri, 05 Jun 2026 16:06:00 -0400 FEMY O.50783454 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+04/26603331.html si-local-file:///var/storage/secattach/20260604/26603331.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+04/26603331.html Thu, 04 Jun 2026 09:00:00 -0400 FEMY O.50783454 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+04/26603331.html si-local-file:///var/storage/secattach/20260604/26603331.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+Jun+04/26603331.html Thu, 04 Jun 2026 09:00:00 -0400 FEMY O.50783454 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+May+13/26487093.html si-local-file:///var/storage/secattach/20260513/26487093.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+May+13/26487093.html Wed, 13 May 2026 16:48:00 -0400 FEMY O.50783454 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+May+13/26487093.html si-local-file:///var/storage/secattach/20260513/26487093.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FEMASYS+INC+++++++++++++++For%3A+May+13/26487093.html Wed, 13 May 2026 16:48:00 -0400 FEMY O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html <p>Femasys Inc. (NASDAQ: FEMY) announced it received CE Mark approval for its FemHSG Catheter, expanding the company's fertility product portfolio in European markets through commercial partners.</p> <p>The FemHSG Catheter is designed for office-based fertility evaluation procedures and works with Femasys' FemVue device to provide ultrasound-based assessment of the uterine cavity and fallopian tubes. The catheter features a small-profile design with a balloon intended to accommodate varying uterine cavity sizes without requiring catheter exchange.</p> <p>The approval allows the company to offer a comprehensive initial fertility workup solution to OB/GYNs and women's health practitioners in Europe. The FemHSG Catheter joins Femasys' existing fertility portfolio, http://www.streetinsider.com/FDA/Femasys+receives+CE+mark+approval+for+FemHSG+fertility+catheter+in+Europe/26482647.html Wed, 13 May 2026 09:00:15 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html <p align="left">ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2qTTAHqWKHFqmQjshN02O4NyKsnEjucvZ0_CJxpof2Oehp95II0AkUmIHgWZhKYn94_SI9Unc9C_EvrO327Lhw==" rel="nofollow" target="_blank">Femasys Inc.</a> (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company’s portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company’s FemVue device for in-office ultrasound-based evaluation.</p> <p>Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html Wed, 13 May 2026 09:00:00 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html <p align="left">ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2qTTAHqWKHFqmQjshN02O4NyKsnEjucvZ0_CJxpof2Oehp95II0AkUmIHgWZhKYn94_SI9Unc9C_EvrO327Lhw==" rel="nofollow" target="_blank">Femasys Inc.</a> (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company’s portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company’s FemVue device for in-office ultrasound-based evaluation.</p> <p>Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html Wed, 13 May 2026 09:00:00 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html <p align="left">ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2qTTAHqWKHFqmQjshN02O4NyKsnEjucvZ0_CJxpof2Oehp95II0AkUmIHgWZhKYn94_SI9Unc9C_EvrO327Lhw==" rel="nofollow" target="_blank">Femasys Inc.</a> (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company’s portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company’s FemVue device for in-office ultrasound-based evaluation.</p> <p>Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html Wed, 13 May 2026 09:00:00 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html <p align="left">ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2qTTAHqWKHFqmQjshN02O4NyKsnEjucvZ0_CJxpof2Oehp95II0AkUmIHgWZhKYn94_SI9Unc9C_EvrO327Lhw==" rel="nofollow" target="_blank">Femasys Inc.</a> (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company’s portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company’s FemVue device for in-office ultrasound-based evaluation.</p> <p>Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html Wed, 13 May 2026 09:00:00 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454 http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html <p align="left">ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2qTTAHqWKHFqmQjshN02O4NyKsnEjucvZ0_CJxpof2Oehp95II0AkUmIHgWZhKYn94_SI9Unc9C_EvrO327Lhw==" rel="nofollow" target="_blank">Femasys Inc.</a> (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG™ Catheter, further expanding the Company’s portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company’s FemVue device for in-office ultrasound-based evaluation.</p> <p>Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is http://www.streetinsider.com/Press+Releases/Femasys+Expands+Fertility+Care+Portfolio+in+Europe+with+CE+Mark+Approval+for+FemHSG%E2%84%A2+Catheter/26482610.html Wed, 13 May 2026 09:00:00 -0400 A.29337264 A.39054418 A.50203494 A.50204279 A.50207506 A.50215734 FEMY O.00051987 O.00259435 O.00527988 O.01235117 O.05372760 O.20041670 O.50783454